US Edition
NovoCure (NVCR) Stock Is Trending Overnight — Here's What You Should Know - NovoCure (NASDAQ:NVCR)
FDA approval based on PANOVA-3 trial shows Optune Pax improves median survival by two months and delays pain progression in pancreatic cancer patients.
- On February 12, 2026, the U.S. Food and Drug Administration approved Optune Pax, NovoCure's portable TTFields device, for locally advanced pancreatic cancer, the first new treatment in nearly 30 years.
- The PANOVA-3 Phase 3 trial showed median overall survival rose to 16.2 months from 14.2 months in 571 patients receiving Optune Pax with gemcitabine and nab-paclitaxel chemotherapy.
- Most patients in PANOVA-3 experienced device-related skin reactions at 76.3%, while one-year overall survival rates rose to 68.1% from 60.2%, Michelle Tarver, MD, PhD, of the FDA said `Pancreatic cancer is one of the most challenging cancers to treat`.
- On Wednesday, NovoCure shares surged 29.52% to $13.60 in after-hours trading, and CEO Frank Leonard said it was a proud moment as the company prepares to bring Optune Pax to patients.
- With revenue of $655 million last year, Novocure saw its share price fall 36%, reflecting weak investor sentiment before the approval.
12 Articles
12 Articles
MedPage Today
Anti-Aging, Acupuncture and Health NewsFirst-of-Its-Kind Device for Pancreatic Cancer Wins FDA Approval
(MedPage Today) -- The FDA approved a tumor treating fields (TTFields) device for locally advanced pancreatic cancer, the first therapy approved in this setting in nearly 30 years. Dubbed Optune Pax, the wearable device delivers alternating electric...
FDA approves first-of-its-kind electric-field device for advanced pancreatic cancer
The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the treatment of locally advanced pancreatic cancer.Optune Pax (Novocure) releases tumor-treating fields — known to disrupt cancer cell division while largely sparing healthy cells — to the abdomen via electrically insulated adhesive patches placed on the
NovoCure (NVCR) Stock Is Trending Overnight — Here's What You Should Know - NovoCure (NASDAQ:NVCR)
NovoCure Ltd (NASDAQ:NVCR) shares are trending on Thursday. Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax for the treatment of locally advanced pancreatic cancer. First Approval In Three Decades The approval marks the first new treatment for locally advanced pancreatic cancer in nearly 30 years, according to the company’s announcement. Optune …
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
